Physician profile
Mark Doherty
NPI 1467423871
$856.39
in general payments reported to CMS, 2019-2025
11 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $445.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $445.56 | 2025 | Core |
| Genentech USA, INC. | $102.26 | 2019 | |
| Merck Sharp & Dohme LLC | $73.13 | 2019 | |
| Clovis Oncology, INC. | $60.32 | 2019 | |
| Coopersurgical, INC. | $50.62 | 2019 | |
| Mylan Institutional INC. | $46.42 | 2019 | |
| Daiichi Sankyo INC. | $20.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.81 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.16 | 2019 | |
| Kyowa Kirin, INC. | $11.75 | 2019 | |
| Olympus America INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.